{"id":"W84242093","doi":"10.7175/fe.v6i4.845","title":"Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato","year":2005,"lang":"en","type":"article","venue":"Farmeconomia Health economics and therapeutic pathways","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Formulary; Ibritumomab tiuxetan; Health care; Clinical trial; Resource consumption; Pediatrics; Internal medicine; Radioimmunotherapy; Family medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002750648,0.0007138296,0.001076709,0.002312157,0.00009331547,0.001327088,0.0004339507,0.0005347395,0.003588862],"category_scores_gemma":[0.007911673,0.0002278573,0.003554115,0.002183947,0.0002964451,0.0005758302,0.0004647012,0.0005798736,0.0002679016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002358579,"about_ca_system_score_gemma":0.0008222183,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004021428,"about_ca_topic_score_gemma":0.003202681,"domain_scores_codex":[0.9976922,0.001399182,0.0001730393,0.0001838135,0.0003877713,0.0001640727],"domain_scores_gemma":[0.9944748,0.004230903,0.0008866572,0.0001448566,0.0001691016,0.00009373996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08743189,0.002250048,0.3291751,0.009219163,0.02483191,0.001074132,0.0003575351,0.201586,0.006377044,0.005783122,0.007133694,0.3247803],"study_design_scores_gemma":[0.005643601,0.02022767,0.8225449,0.001292776,0.02540647,0.002995539,0.0003900289,0.08874368,0.005470839,0.00310927,0.02401925,0.0001560273],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9337845,0.04652774,0.002480463,0.0009263633,0.00008570708,0.000411936,0.00696164,0.00004953269,0.008772084],"genre_scores_gemma":[0.983682,0.007287053,0.002107304,0.0002032641,0.0001010432,0.0003074626,0.004787385,0.00004240311,0.001482108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004021428,"threshold_uncertainty_score":0.01711279,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03793197532515781,"score_gpt":0.2879080719108901,"score_spread":0.2499760965857323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}